Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia

Journal of Cancer Research and Clinical Oncology

Volumn 126, Issue 3, 2000, Pages 173-177

  Gerke, Peter ^b   Filejski, Wojciech ^c   Robins, H Ian ^a   Wiedemann, Günther J ^c   Steinhoff, Jürgen ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NONE

Author keywords

Carboplatin; Etoposide; Ifosfamide; Nephrotoxicity; Whole body hyperthermia

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHERMIC THERAPY; INTERMETHOD COMPARISON; KIDNEY TUBULE; MALE; MOLECULAR WEIGHT; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0034012502     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050028     Document Type: Article

References (23)

1. Agaliotis DP, Ballester OF, Mattox T, Hiemenz JW, Fields KK, Zorsky PE, Goldstein SC, Perkins JB, Rosen RM, Elfenbein GJ (1997) Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation. Am J Med Sci 314:292-298
2. Bakhshandeh A, Bath V, Wiedemann GJ, Longo W, Lerner BM, Tiggelaar CL, Robins HI (1999) Year 2000 guidelines for clinical practice of whole body hyperthermia combined with cytotoxic drugs from the University of Lübeck, Germany and the University of Wisconsin, USA. J Oncol Pharm Pract (in press)
3. Boesken WH, Maimier A, Neumann H, Engelhard R (1983) Does febrile proteinuria exist? Klin Wochenschr 61:917-922
4. Brauer LP, Prieshof B, Wiedemann GJ, Weiss C, Kriz W, Schramm U, Robins HI, Pagel H (1998) Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity. J Cancer Res Clin Oncol 124:549-554
5. Curt GA, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE, Collins JM (1983) A phase I and pharmacokinetic study of diaminecyclobutane dicarboxylatoplatinum (NSC 241240). Cancer Res 43:4470-4473
6. Elkon D, Fechner RE, Homzie MJ, Baker DG, Constable WC (1982) Response of mouse kidney to hyperthermia. Arch Pathol Lab Med 104:153-158
7. Hemmingsen L, Skaarup P (1987) Urinary excretion of ten plasma proteins in patients with febrile diseases. Acta Med Scand 201:359-364
8. Metz-Kurschel U, Kurschel E, Niederle N, Aulbert E (1990) Investigations of the acute and chronic nephrotoxicity of the new platinum analogue carboplatin. J Cancer Res Clin Oncol 116:203-206
9. Ohno S, Strebel FR, Stephens LC, Siddik ZH, Makino M, Klostergaard J, Tomasovic SP, Khokar AR, Bull JMC (1992) Increased therapeutic efficacy by tumor necrosis factor combined with platinum complexes and whole body hyperthermia in rats. Cancer Res 52:4096-4101
10. Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, Ragab A, Wharam M, Wiener E, Maurer H (1994) Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. Am J Pediatr Hematol Oncol 16:286-295
11. Robins HI, Cohen JD, Neville AJ (1992) Whole body hyperthermia: biological, physical and clinical aspects (Clinical Thermology Series). Springer, Berlin Heidelberg New York, pp 1-84
12. Robins HI, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Azoomanian RZ, Alberti D, d'Oleire F, Longo W, Heiss C (1993) Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 11:1787-1794
13. Robins HI, Schmitt-Tiggelaar CL, Cohen JD, Woods JP, Heiss C, Gillis W, d'Oleire F (1994) A new technical approach to radiant heat whole-body hyperthermia. Cancer Lett 79:137-145
14. Rossi RM, Kist C, Wurster U, Kulpmann WR, Ehrich JH (1994) Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis. Pediatr Nephrol 8:151-156
15. Skinner R, Pearson ADJ, Price L, Coulthard MG, Craft AW (1990) Nephrotoxicity after ifosfamide. Arch Dis Child 65:732-738
16. Steinhoff J, Einecke G, Niederstadt C, De Groot K, Fricke L, Machnik H, Sack K (1997) Renal graft rejection or urinary tract infection? The value of myeloperoxidase, C-reactive protein, and α2-macroglobulin in the urine. Transplantation 64:443-447
17. Wiedemann GJ, Roszinski S, Biersack A, Weiss C, Wagner T (1992) Local hyperthermia enhances cyclophosphamide, ifosfamide, and cis-diamminedichloroplatinum cytotoxicity on human derived breast carcinoma and sarcoma xenografts in nude mice. J Cancer Res Clin Oncol 118:129-135
18. Wiedemann GJ, Siemens J, Mentzel M, Biersack A, Wössmann W, Knocks D, Weiss C, Wagner T (1993) Effects of temperature on the therapeutic efficiacy and pharmacokinetic of ifosfamide. Cancer Res 53:4268-4272
19. Wiedemann GJ, d'Oleire F, Knop E, Eleftheriadis S, Bucsky P, Feddersen S, Klouche M, Geisler J, Mentzel M, Schmucker P, Feyerabend T, Weiss C, Wagner T (1994) Ifosfamide and carboplatin combined with 41.8°C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res 54:5346-5350
20. Wiedemann GJ, Katschinski DM, Mentzel M, Wagner T, Touhidi R, d'Oleire F, Robins HI (1996a) Ifosfamide, carboplatin and etoposide (ICE) combined with Aquatherm induced 41.8°C whole-body hyperthermia (WBH) for refractory sarcoma. J Clin Oncol 14:1751
21. Wiedemann GJ, Robins HI, Gutsche S, Mentzel M, Deeken M, Katschinski DM, Eleftheriadis S, Crahe R, Weiss C, Storer B, Wagner T (1996b) Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8°C whole body hyperthermia in patients with refractory sarcoma: a phase II study. Eur J Cancer 32A:888-892
22. Wiedemann GJ, Robins HI, Katschinski DM, Mentzel M, d'Oleire F, Kutz M, Wagner T (1997) Systemic hyperthermia and ICE chemotherapy for sarcoma patients: rationale and clinical status. Anticancer Res 17:2899-2902
23. Wood WG, Herhahn D, Steinhoff J, Feddersen A, Schulz E, Sack K (1990) The diagnostic relevance of specific urinary proteins after renal transplantation. Ärztl Lab 36:260-267